R-848 [144875-48-9]

Catalog number: AG-CR1-3582-M005
Brand: AdipoGen Life Sciences
Packing: 5 mg
Other sizes: 25 mg
Price: € 65.00
Expected delivery time: 7 days
Quantity:
Chemical Structure

Product specifications for - R-848 [144875-48-9]

Overview: 
Product group: Chemicals
Category: Other
Source: Synthetic.
CAS No.: 144875-48-9
Properties: 
Purity: >98%
Molecular Formula: C17H22N4O2
Molecular weight: 314.4
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Storage instructions: Store at -20°C
Scientific information: 
Scientific info: Immune response modifier. Potent antitumor and antiviral compound. Stimulates antibody secretion and cytokine production. Used as adjuvant to increase the effectiveness of vaccines. Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human. Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-kappaB. NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I. Upregulator of the opioid growth factor receptor. Used in the treatment of skin lesions such as herpes simplex virus.
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: AG-CR1-3582-M005; AdipoGen Life Sciences; Resiquimod; S 28463; R848
Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999) Read more
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000) Read more
The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001) Read more
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002) Read more
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002) Read more
Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005) Read more
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005) Read more
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006) Read more
Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.; BBRC 361, 537 (2007) Read more
Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review) Read more